# RIT-Bridge

> RIT-Bridge is a research-use transcriptomic scoring workbench for studying radiotherapy-induced immunotherapy gain, with an initial evidence focus on lung cancer and NSCLC.

Canonical URL: https://rit-bridge.org/
Version: 0.2-alpha
Creator and maintainer: Yueyang Yu
Language: English

## Core outputs

- RIT-Gain: a cohort-relative score indicating how strongly a sample resembles a radiotherapy-induced immunotherapy gain-like molecular state.
- RT convertibility: a cohort-relative estimate of radiotherapy priming potential that combines immune competence with lower immune-barrier burden.
- Uncertainty: a warning layer that increases when evidence coverage is weak or core biological modules disagree.
- Signature coverage: the proportion of model genes represented in the uploaded expression matrix.
- Contribution analysis: an explanation of which radioimmune modules raise or lower each sample score.

## Intended use

RIT-Bridge supports hypothesis generation, sample prioritization, and transparent exploration of bulk RNA-seq matrices in radiotherapy-immunotherapy research.

## Scientific boundary

RIT-Bridge is not clinically validated. Its scores are relative to the submitted cohort and are not treatment-benefit probabilities. The website must not be used for diagnosis, patient-level treatment selection, or clinical decision-making.

## Evidence and method

The model integrates radiotherapy priming, immune-effector, immune-barrier, checkpoint-context, and proliferation-context programs. The public website provides an evidence atlas, validation notes, limitations, version notes, and browser-side contribution analysis.

## Citation

Yu Y. RIT-Bridge v0.2: a research-use framework for estimating radiotherapy-induced immunotherapy gain from transcriptomic data. 2026.

## Contact and feedback

Project website: https://rit-bridge.org/
Feedback survey: https://wj.qq.com/s2/28043015/0exf/